5 domestic pharmaceutical companies to buy foreign products for what?

Medicine Network February 10th, with the beginning of the "two-vote system" national version of the program and the comprehensive promotion of the introduction of disease-based charges related policies, 2017 is destined to be an extraordinary yearIndustry analysis, under the current compliance requirements, foreign investment is not willing to cause trouble, as a multinational pharmaceutical company, once in China is punished, in foreign countries may also be jointly punished, the consequences are very seriousWhen sales are outsourced, the risk is much lessin fact, since 2015, foreign pharmaceutical companies have been cutting costs by divesting non-core businessesA growing number of foreign pharmaceutical companies are doing business with local pharmaceutical companies on a product line in ChinaThis is also One of the important reasons for Lilly, Novartis, GSK, etc., to transfer some of the distribution rights to local operators in China last yearIt can be predicted that this form of commercial cooperation between foreign capital and domestic pharmaceutical companies will remain the trend in 2017domestic pharmaceutical companies to acquire mature products from a foreign product line
AstraZeneca and Kangzhe Pharmaceuticals signed an exclusive license agreement on February 26, 2016, and Kangzhe Pharmaceuticals will pay AstraZeneca $310 million to obtain exclusive rights to Poitin's commerciallicensed products in ChinaAt the same time, Everest Future, a subsidiary of Tibet Pharmaceuticals, a largest shareholder of the A-share listed company, purchased AstraZeneca's products and brand-related assets worldwide (except the United States) for $190 millionOn May 19, 2016, Tyling Pharmaceuticals Announced an agreement with Novartis Pharmaceuticals to acquire internationally renowned orthopaedic brand seal interest, related intellectual property rights, licenses and other assets in a transaction valueof $145 millionOn July 4, 2016, GlaxoSmithKline (GSK) China announced the transfer of its stake in Nanjing Meri Pharmaceuticals, the Murray plant, and local production and supply operations related to three urinary products (Schoiniting Express, Schoenating Andnato) will be operated by Cadela under existing legal entitiesOn October 11, 2016, Sansheng Hong Kong Sansheng, a wholly owned subsidiary of Sansheng Pharmaceuticals, signed an exclusive license agreement with AstraZeneca, which grants Sansheng Hong Kong exclusive rights to commercialize the diabetes drug Byetta (Essenapeptide Injection) and Bydureon (Essenapeptide's reprieve agent) in ChinaNovember 9, 2016 - Lilly China announced that it has reached an exclusive agreement with The Chinese pharmaceutical company Eten Pharmaceuticals to formally award Eoten Pharmaceuticals the promotion and distribution rights of its antibiotic products within the scope of Chinese mainland from January 1, 2017why domestic pharmaceutical companies are willing to throw heavy gold "receiving"Boydin and Imdo Boydin (non-Lotte flat release tablets) produced by AstraZeneca original research, for
the treatment of high blood pressure and stable angina, belong to the National Health Insurance Class B drugs Imdo (mononitric acid isobic perterirate tablet) was developed by AstraZeneca for coronary heart disease ischemic treatment, launched in Europe in 1985, sold in more than 40 countries around the world, and sold nearly $57 million outside the United States in 2015 as can be seen from Figure 1, non-Lodiping and mononitric acid isotopacid pears in the past two years in China's urban public hospitals, county-level public hospitals, urban communities and township hospitals in the four chemical drug patterns have a good sales volume, of which non-Lodiping two years in the four major chemical drug market sales of more than 1 billion yuan Sales of more than one billion varieties, large enough, for the existing hospital channels penetration is very deep, its own gold content is sufficient Kangzhe Pharmaceuticals, from the point of view of the product line, BoYeding and the company now sales coverage of the city, hospital channels are 50% coincide, the existing cardiovascular line market to form a complementary, can be quickly integrated into the company's existing product line, so that the company benefits cover Novartis brand drug cover (salmon calcitin) belongs to the health insurance Class B drug, mainly used to treat osteoporosis, hypercalcemia As a global well-known brand in the field of orthopaedics, the mi-gai products have long maintained a stable sales revenue, and has a global sales network can be seen by the rice data, in the past two years, salmon calcitin in China's urban public hospitals, county-level public hospitals, urban communities and township hospitals in the four chemical patterns of total sales of more than 300 million yuan China has 21 million osteoporosis patients, only more than 1.4 million access to therapeutic drugs, the market space is vast acquisition of the Migai brand, will enrich the Thai ling
pharmaceutical the existing four major therapeutic areas of cancer, central nervous, liver disease and respiratory system product line, strategic access to the field of orthopaedics The handover will generate substantial revenue and profits for the company Schenypavilion quick release tablets, Schoenating slow-release tablets and Nato
Nanjing Meirui Pharmaceutical Co., Ltd.'s Schoenytin express release tablets (tartaric acid totrostro-speed release tablets), Scheritin slow release tablets (tartaric acid totrostin reprieve) and Nato (nich tablets) are three types of urinary products, all of which are medical lybs, of which Schoenatin slow release tablets are the exclusive varieties of the company figure 3 shows that Totrosain and Niylare are sold in the
four chemical patterns of the city's public hospitals, the county-level public hospitals, the urban community and the township hospitals Cadelsta Pharmaceutical Holdings Group in the antibiotic market, cardiovascular market, liver disease, tumor products have a layout, Nanjing Merry Pharmaceutical Co., Ltd.'s urology portfolio will undoubtedly fill the gap in the field of Cadstar's existing business Isenapeptide Byetta (Essena peptide injection) as an exclusive astravanaric variety for improving blood sugar control in patients with type 2 diabetes, was approved by the FDA in 2005 and went on the market by the CFDA in 2009 Bydureon is a slow-release agent for Essenapeptide for blood sugar control in patients with type 2 diabetes figure 4 shows that in 2014-2015, Essenade's total sales in the four chemical drug patterns of urban public hospitals, county-level public hospitals, urban communities and township hospitals increased year by year, with sales exceeding 100 million yuan in 2015 and growth rates of more than 75% in both years this strategic partnership with AstraZeneca has enabled the Sansheng Pharmaceuticals product line to expand and penetrate the market in the area of diabetes, a major chronic disease The company will enter the diabetes industry, which could be another growth driver for the company in the future Hicklau®
and stable ®
Hicklau ® (Head Spore Clo reprieve (II),) entered China in 1993 and became a brand of oral antimicrobial drugs with high recognition by doctors in China Stable and credible ® (injected vancomycin hydrochloride) entered the Chinese market in 1996 and, due to its excellent efficacy and good safety, became the gold standard for the treatment of MRSA (methicillin-resistant Staphylococcus aureus) infection According to the data of Minet, vancomycin and cephalosporine have totalsales of more than 100 million yuan in the four chemical drug patterns of China's urban public hospitals, county-level public hospitals, urban communities and township hospitals in the past three years, and the total sales of vancomycin in 2015 were nearly 1 billion yuan This strategic cooperation will undoubtedly increase its content strength in the field of anti-infection, but also further enhance the core competitiveness of Eteng Pharmaceuticals conclusion
in 2017, this form of cooperation will continue, we look forward to the next "catcher" appear!